The findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4.
Abstract
Dysregulation of long non-coding RNAs (lncRNAs) plays a significant role in the progression of hepatocellular carcinoma (HCC), yet many underlying mechanisms remain elusive. Recent studies have highlighted the critical importance of internal N
7
-methylguanosine (m
7
G) modifications in influencing RNA expression and function. In this study, we identified LINC01252, a poorly characterized lncRNA, through analyses of GEO datasets and the TCGA cohort. Notably, LINC01252 is downregulated in HCC tissues and is associated with prognostic outcomes, although the predictive value of a nomogram based on LINC01252 expression characteristics appears to be limited. Our results indicate that LINC01252 effectively inhibits tumorigenic behaviors in HCC and exerts its effects by targeting the oncogene NUPR1. Mechanistically, LINC01252 acts as an intranuclear lncRNA that binds to the NUPR1 promoter through Hoogsteen pairing, consequently inhibiting its transcriptional activity. Additionally, the internal m
7
G modification level of LINC01252 directly influences its RNA stability, contingent upon sufficient concentrations of S-adenosylmethionine (SAM), which is necessary for the activity of its key modifying enzymes, METTL1 and WDR4. Thus, LINC01252’s m
7
G modification and expression are SAM-dependent in the context of HCC. Furthermore, LINC01252 can also suppress WDR4 transcription by binding to its promoter through the same mechanism, thus inhibiting HCC progression. Our findings suggest that LINC01252 functions as a SAM-dependent, m
7
G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4. However, the potential of LINC01252 as a clinical biomarker still requires further investigation.
It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.
Ze-Kai Li, Min Luo, Shu-Sen Fang et al.· Analytical Cellular Patholog...· 0 citations
A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.
It is suggested that the LINC01446/miR-338-3p/APEX1 axis may contribute to ESCC progression and ferroptosis defense, warranting further investigation into its potential therapeutic and prognostic value.
This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.
Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al.· Current Genetic Medicine Rep...· 0 citations
A potential oncogenic pathway was delineated in which NPC migration and invasion were facilitated by YTHDF2 via degradation of circ_0015508, thereby the sponging effect of miR-496 was abolished and FOXN3 expression was suppressed.
Ai-Yu Ma, Xu Wang, Lu Lu et al.· Oncology Research· 0 citations
It is revealed that METTL14-dependent m6A modification of MSTRG.16 may act as an upstream driver to activate the MAPK cascade and facilitate NSCLC progression.
Qin-Fang Deng, Hui Sun, Heyong Wang et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.